会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
    • 三氮唑嘧啶衍生物作为GLYCOGEN SYNTHASE激酶3抑制剂
    • WO2005012304A2
    • 2005-02-10
    • PCT/EP2004/051457
    • 2004-07-12
    • JANSSEN PHARMACEUTICA N.V.FREYNE, Eddy, Jean, EdgardLOVE, Christopher, JohnCOOYMANS, Ludwig, PaulVANDERMAESEN, NeleBUIJNSTERS, Peter, Jacobus, Johannes, AntoniusWILLEMS, MarcEMBRECHTS, Werner, Constant, Johan
    • FREYNE, Eddy, Jean, EdgardLOVE, Christopher, JohnCOOYMANS, Ludwig, PaulVANDERMAESEN, NeleBUIJNSTERS, Peter, Jacobus, Johannes, AntoniusWILLEMS, MarcEMBRECHTS, Werner, Constant, Johan
    • C07D487/00
    • C07D487/04
    • This invention concerns compounds of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochernically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R 1 represents hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 a]kyl; C 1-6 alkyloxycarbonyl; C 1-6 alkyl substituted with formyl, C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylcarbonytoxy; or optionally substituted C 1-6 alkyloxyCl-6alkylcarbonyl; X 1 represents a direct bond; -(CH 2 ) n3 - or -(CH 2 ) n4 -X 1a -X 1b -; R 2 represents optionally substituted C 3-7 CYCloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatorn selected from 0, S or N; benzoxazolyl or a radical of formula (a-1); X 2 represents a direct bond; -NR 1 -NR 1 -(CH 2 ) N3 -; -0-; -0-(CH 2 ) n3 -; -C(=O)-; -C(=O)- (CH 2 ) n3 -; -C(=O)-NR 5 -(CH 2 ) n3 -; -C(=S)-; -S-; -S(=O) n1 -; -(CH 2 ) n3 -; -(CH 2 ) n4 -X 1a -X 1b -; -X 1a .-X 1b -(CH 2 ) n4 -; -S(=O) n1 -NR 5 -(CH 2 ) n3 -NR 5 _ or -S(=O) n1 ,-NR 5 -(CH 2 ) n3 -; R 3 represents an optionally substituted 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from 0, S or N, or a 9-or 10-membered bicyclic heterocycle containing at least one heteroatom selected from 0, S or N; R 4 represents hydrogen; halo; hydroxy; optionally substituted C 1-4 alkyl; optionally substituted C 2-4 alkenyl or C 2-4 alkynyl; polyhaloC 1-3 alkyl; optionally substituted C 1-4 alkyloxy; polyhaloC 1-3 alkyloxy; C 1-4 alkylthio; polyhaloC 1-3 alkylthio; C 1-4 alkyloxycarbonyl; C 1-4 alkylcarbonyloxy; C 1-4 alkylcarbonyl; polyhaloC 1-4 alkylcarbonyl; nitro; cyano; carboxyl; NR 9 R 10 ; C(=O)NR 9 R 10 ;-NR 5_ C(=O)-NR 9 R 10 ; -NR 5 -C(=O)-R 5 ; -S(=O) n1 ,-R 11 -NR 5 -S(=O) n1 ,-R 11 -S-CN; -NR 5 -CN; their use, pharmaceutical compositions comprising them and processes for their preparation.
    • 本发明涉及式(I)的化合物,N-氧化物,药学上可接受的加成盐,季胺及其立体异构体形式,其中环A表示苯基,吡啶基,嘧啶基,哒嗪基或吡嗪基; R 1表示氢; 芳基; 甲酰基; C 1-6烷基羰基; C 1-6 a] kyl; C 1-6烷氧基羰基; 被甲酰基,C 1-6烷基羰基,C 1-6烷氧基羰基,C 1-6烷基羰基氧基取代的C 1-6烷基; 或任选取代的C 1-6烷氧基C 1-6烷基羰基; X1表示直接键; - (CH 2)n3-或 - (CH 2)n4-X1a-X1b-; R 2表示任选取代的C 3-7C环烷基; 苯基; 含有至少一个选自0,S或N的杂化剂的4,5,6-或7-元单环杂环; 苯并恶唑基或式(a-1)基团; X2表示直接键; -NR 1 -NR 1 - (CH 2)N 3 - ; -0-; -O-(CH 2)N 3 - ; -C(= O) - ; -C(= O) - (CH 2)n3-; -C(= O)-NR <5> - (CH2)N3-; -C(= S) - ; -S-; -S(= O)N 1 - ; - (CH2)N3-; - (CH 2)N 4 - X1A-X1b-; -X1a.-X1b-(CH2)N4-; -S(= O)n1-NR5 - (CH2)n3-NR5或-S(= O)n1,-NR5 - (CH2)n3-; R 3表示含有至少一个选自O,S或N的杂原子或含有至少一个选自O,S或S的杂原子的9元或10元双环杂环的任选取代的5元或6元单环杂环, N; R 4表示氢; 光环; 羟基; 任选取代的C 1-4烷基; 任选取代的C 2-4烯基或C 2-4炔基; polyhaloC1-3alkyl; 任选取代的C 1-4烷氧基; polyhaloC1-3alkyloxy; C1-4alkylthio; polyhaloC1-3alkylthio; C1-4alkyloxycarbonyl; C1-4alkylcarbonyloxy; C1-4alkylcarbonyl; polyhaloC1-4alkylcarbonyl; 硝基; 氰基; 羧基; NR <9> - [R <10>; C(= O)NR <9> - [R <10>; - NR <5_> C(= O)-NR <9> - [R <10>; -NR <5> C(= O)-R <5>; -S(= O)n1,-R 11 -NR 5 -S(= O)n1,-R 11 -S-CN; -NR 5 -CN; 其用途,包含它们的药物组合物及其制备方法。
    • 6. 发明申请
    • CYCLIC ANILINO - PYRIDINOTRIAZINES
    • CYCLIC ANILINO - PYRIDINOTRIAZINES
    • WO2007003525A2
    • 2007-01-11
    • PCT/EP2006/063555
    • 2006-06-26
    • JANSSEN PHARMACEUTICA N.V.ROMBOUTS, Frederik, Jan, RitaLOVE, Christopher, JohnVAN EMELEN, KristofVAN BRANDT, Sven, Franciscus, AnnaWU, Tongfei
    • ROMBOUTS, Frederik, Jan, RitaLOVE, Christopher, JohnVAN EMELEN, KristofVAN BRANDT, Sven, Franciscus, AnnaWU, Tongfei
    • C07D487/18C07D251/16C07D401/04C07D471/18C07D471/22C07D487/08
    • The present invention concerns the compounds of formula (I), the N -oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents 1, n represents 1, Z represents N or C, in particular N; -X 1 - represents C 1-4 alkyl, in particular methyl; -X 2 - represents -C 1-4 alkyl- or -C 1-4 alkyl-NR 7 -, in particular propyl, -ethyl-NR 7 - or -propyl-NR 7 -; -Y- represents-NR 2 -C 1-6 alkyl-CO-NR 4 -, -Het 1 -C 1-6 alkyl-CO-NR 5 - or -Het 2 -CO-NR 6 - and wherein the -C 1-6 alkyl- linker of -NR 2 -C 1-6 alkyl-CO-NR 4 - or -Het 1 -C 1-6 alkyl-CO-NR 5 - is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo and phenyl; R 1 represents hydrogen, chloro, fluoro or bromo; R 2 represents -C 1-4 alkyl-, in particular ethyl or methyl; R 7 represents hydrogen; R 8 represents hydrogen; R 4 , R 5 and R 6 represent hydrogen; Het 1 is selected from piperazinyl or piperidinyl, in particular -piperazinyl; Het 2 selected from pyrrolidinyl or piperidinyl, in particular pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy.
    • 本发明涉及式(I)化合物,N-氧化物形式,其药学上可接受的加成盐和立体化学异构形式,其中m表示1,n表示1,Z表示N或C,特别是N; -X 1表示C 1-4烷基,特别是甲基; -X 2 - 表示-C 1-4烷基 - 或-C 1-4 - 烷基-NR 7 - - ,特别是丙基, - 乙基-NR 7 - 或 - 丙基-NR 7 - ; -Y-表示-NR 2 -C 1-6烷基-CO-NR 4 - ,-Het 1 SUP / > -C 1-6烷基-CO-NR 5 - 或-Het 2 -CO-NR 6 - - 并且其中-NR 2 -C 1-6烷基-CO-NR的-C 1-6烷基 - 连接基团, 4 - 或-Het 1 -C 1-6烷基-CO-NR 5 - 任选被一个或多个 可能的两个或更多个选自羟基,卤素和苯基的取代基; R 1表示氢,氯,氟或溴; R 2表示-C 1-4 - 烷基 - ,特别是乙基或甲基; R 7表示氢; R 8表示氢; R 4,R 5和R 6表示氢; Het 1选自哌嗪基或哌啶基,特别是哌嗪基; Het 2选自吡咯烷基或哌啶基,特别是吡咯烷基,其中所述吡咯烷基任选被羟基取代。
    • 8. 发明公开
    • TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
    • 三唑衍生物作为抑制剂糖原合酶激酶3
    • EP1781659A2
    • 2007-05-09
    • EP04766191.3
    • 2004-07-12
    • JANSSEN PHARMACEUTICA N.V.
    • FREYNE, Eddy, Jean, EdgardLOVE, Christopher, JohnCOOYMANS, Ludwig, PaulVANDERMAESEN, NeleBUIJNSTERS, Peter, Jacobus, Johannes, AntoniusWILLEMS, MarcEMBRECHTS, Werner, Constant, Johan
    • C07D487/00
    • C07D487/04
    • This invention concerns compounds of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochernically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 represents hydrogen; aryl; formyl; C1-6 alkylcarbonyl; C1-6 a]kyl; C1-6 alkyloxycarbonyl; C1-6 alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonytoxy; or optionally substituted C1-6 alkyloxyCl-6alkylcarbonyl; X1 represents a direct bond; -(CH2)n3- or -(CH2)n4-X1a-X1b-; R2 represents optionally substituted C3-7CYCloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatorn selected from 0, S or N; benzoxazolyl or a radical of formula (a-1); X2 represents a direct bond; -NR1-NR1-(CH2)N3 -; -0-; -0-(CH2)n3-; -C(=O)-; -C(=O)- (CH2)n3-; -C(=O)-NR5-(CH2)n3-; -C(=S)-; -S-; -S(=O)n1-; -(CH2)n3-; -(CH2)n4-X1a-X1b-; -X1a.-X1b-(CH2)n4-; -S(=O)n1-NR5-(CH2)n3-NR5_ or -S(=O)n1,-NR5 -(CH2)n3-; R3 represents an optionally substituted 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from 0, S or N, or a 9-or 10-membered bicyclic heterocycle containing at least one heteroatom selected from 0, S or N; R4 represents hydrogen; halo; hydroxy; optionally substituted C1-4alkyl; optionally substituted C2-4alkenyl or C2-4alkynyl; polyhaloC1-3alkyl; optionally substituted C1-4alkyloxy; polyhaloC1-3alkyloxy; C1-4alkylthio; polyhaloC1-3alkylthio; C1-4alkyloxycarbonyl; C1-4alkylcarbonyloxy; C1-4alkylcarbonyl; polyhaloC1-4alkylcarbonyl; nitro; cyano; carboxyl; NR9R10; C(=O)NR9R10;-NR5_C(=O)-NR9R10; -NR5-C(=O)-R5; -S(=O) n1,-R11 -NR5-S(=O)n1,-R11 -S-CN; -NR5 -CN; their use, pharmaceutical compositions comprising them and processes for their preparation.